stockrow
Friday 6 November 2026
Export IMNM’s income statement to Excel — free account
Immunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
18.65
0.74
+4.13%
Follow IMNM
Alert me
Immunome, Inc. (IMNM) Gross margin
Immunome, Inc.'s gross margin over the twelve months to 30 June 2025 was 100.0%. Over the past ten years it has ranged from 0.00% (fiscal 2022) to 100.0% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 100.0% | 0.00 |
| FY2024 | 100.0% | 0.00 |
| FY2023 | 100.0% | 100.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2025 | 100.0% | 0.00 |
| Mar 2025 | 100.0% | 0.00 |
| Dec 2024 | 100.0% | 0.00 |
| Sep 2024 | 100.0% | 0.00 |
| 19 more quarters | Free account |
Against its own ten years
Low 0.00%
High 100.0%
Ten-year median
0.00%
Current reading's percentile
100
Gross margin against peers
| Company | Gross margin |
|---|---|
| IMNM Immunome, Inc. | 100.0% |
| CLDX Celldex Therapeutics, Inc. compare | 100.0% |
| PVLA Palvella Therapeutics, Inc. compare | 100.0% |
| AUPH Aurinia Pharmaceuticals Inc compare | 90.6% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 89.8% |
| VCEL Vericel Corporation compare | 74.5% |
| ADMA ADMA Biologics Inc compare | 68.5% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on IMNM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement